Bulent Zulfikar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bulent Zulfikar has a total of 342 co-authors. Here are the top co-authors by number of shared publications:
- Basak Koc
Department of Pediatrics Pediatric Hematology‐Oncology Division Institute of Oncology Istanbul University Istanbul Turkey
15 shared publications - Rejin Kebudi
Department of Pediatric Hematology and Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye
7 shared publications - Ulku Miray Yildirim
Division of Pediatric Hematology-Oncology, Institute of Oncology, İstanbul University, İstanbul, Türkiye
6 shared publications - Flora Peyvandi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
4 shared publications - Kaan Kavakli
Department of Pediatrics Ege University Faculty of Medicine Bornova Turkey
4 shared publications - Canan Albayrak
Department of Pediatric Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Türkiye
3 shared publications
Latest Publications
- 30 October 2026
- Published by Istanbul University in The Journal of Child
- Vol. 26 (3) , 237-243
Arthropathy in Hemophilia Despite Prophylaxis: The Role of Cumulative Disease Burden Rather Than Bleeding Frequency
Introduction: Hemophilia A and B are inherited bleeding disorders characterized by recurrent bleeding episodes that can lead to progressive arthropathy, particularly in large joints. Although prophylactic factor replacement therapy reduces bleeding frequency, joint damage may continue to develop in some patients. The aim of this study was to evaluate the factors that determine the development of arthropathy in hemophilia patients receiving prophylaxis.Materials and Methods: This retrospective single-center study included 99 pediatric patients with hemophilia A or B who were followed between 2000 and 2018. Demographic characteristics, disease severity, duration of prophylaxis, follow-up duration, annual bleeding rate (ABR), annual joint bleeding rate (AJBR), and the presence of arthropathy were evaluated. Univariate logistic regression and correlation analyses were performed to identify the factors associated with arthropathy.Results: Of the 99 patients, 76.8% had hemophilia A and 23.2% had hemophilia B. Most patients with severe hemophilia received regular prophylactic treatment. Although baseline factor levels differed significantly according to disease severity, ABR and AJBR were comparable among patients receiving prophylaxis. Increasing age and longer follow-up duration were significantly associated with arthropathy, whereas ABR, AJBR, and factor level were not. Correlation analysis also demonstrated a significant positive association between follow-up duration and arthropathy, whereas no significant association was observed between bleeding parameters and joint damage.Conclusion: In patients with hemophilia receiving prophylaxis, the development of arthropathy appears to be associated with the cumulative burden of the disease and the duration of exposure rather than with the current bleeding frequency. These findings emphasize the importance of the early initiation and maintenance of prophylactic treatment in preventing long-term joint damage.
- 30 October 2026
- Published by Istanbul University in The Journal of Child
- Vol. 26 (3) , 237-243
Arthropathy in Hemophilia Despite Prophylaxis: The Role of Cumulative Disease Burden Rather Than Bleeding Frequency
Introduction: Hemophilia A and B are inherited bleeding disorders characterized by recurrent bleeding episodes that can lead to progressive arthropathy, particularly in large joints. Although prophylactic factor replacement therapy reduces bleeding frequency, joint damage may continue to develop in some patients. The aim of this study was to evaluate the factors that determine the development of arthropathy in hemophilia patients receiving prophylaxis.Materials and Methods: This retrospective single-center study included 99 pediatric patients with hemophilia A or B who were followed between 2000 and 2018. Demographic characteristics, disease severity, duration of prophylaxis, follow-up duration, annual bleeding rate (ABR), annual joint bleeding rate (AJBR), and the presence of arthropathy were evaluated. Univariate logistic regression and correlation analyses were performed to identify the factors associated with arthropathy.Results: Of the 99 patients, 76.8% had hemophilia A and 23.2% had hemophilia B. Most patients with severe hemophilia received regular prophylactic treatment. Although baseline factor levels differed significantly according to disease severity, ABR and AJBR were comparable among patients receiving prophylaxis. Increasing age and longer follow-up duration were significantly associated with arthropathy, whereas ABR, AJBR, and factor level were not. Correlation analysis also demonstrated a significant positive association between follow-up duration and arthropathy, whereas no significant association was observed between bleeding parameters and joint damage.Conclusion: In patients with hemophilia receiving prophylaxis, the development of arthropathy appears to be associated with the cumulative burden of the disease and the duration of exposure rather than with the current bleeding frequency. These findings emphasize the importance of the early initiation and maintenance of prophylactic treatment in preventing long-term joint damage.
- Open Access
- 1 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
The Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries – For Whom, by Whom and Where?
Hemophilia, a congenital deficiency of factor VIII (hemophilia A) or factor IX (hemophilia B), leads to recurrent bleeding episodes that may cause progressive joint damage and long-term disability. Traditional management relies on intravenous factor replacement therapy; however, limited half-life, immunogenicity, venous access challenges, and the burden of frequent infusions have prompted the development of extended half-life (EHL) factor products. Although EHL therapies represent an important advancement, they only partially reduce treatment burden and do not fully meet expectations for improved convenience and sustained bleed protection. Recent innovations are reshaping the therapeutic landscape. Nonfactor subcutaneous therapies such as anti-TFPI molecules, antithrombin reducing agents, and anti-protein C agents offer simplified administration with the potential for improved adherence. Gene therapy provides the prospect of a long-term therapeutic effect in selected patients. In Türkiye, hemophilia care remains largely factor-based; however, clinical trial participation and recent regulatory approvals for selected novel therapies have begun to expand real-world experience with these emerging treatment options. As global practice shifts toward individualized, less invasive treatment approaches, expanding availability of novel therapies and optimizing patient-specific treatment strategies will be essential. This review examines current and evolving treatment options, key challenges, and future opportunities shaping the trajectory of hemophilia management.
- 1 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Open AccessThe Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries – For Whom, by Whom and Where?
Hemophilia, a congenital deficiency of factor VIII (hemophilia A) or factor IX (hemophilia B), leads to recurrent bleeding episodes that may cause progressive joint damage and long-term disability. Traditional management relies on intravenous factor replacement therapy; however, limited half-life, immunogenicity, venous access challenges, and the burden of frequent infusions have prompted the development of extended half-life (EHL) factor products. Although EHL therapies represent an important advancement, they only partially reduce treatment burden and do not fully meet expectations for improved convenience and sustained bleed protection. Recent innovations are reshaping the therapeutic landscape. Nonfactor subcutaneous therapies such as anti-TFPI molecules, antithrombin reducing agents, and anti-protein C agents offer simplified administration with the potential for improved adherence. Gene therapy provides the prospect of a long-term therapeutic effect in selected patients. In Türkiye, hemophilia care remains largely factor-based; however, clinical trial participation and recent regulatory approvals for selected novel therapies have begun to expand real-world experience with these emerging treatment options. As global practice shifts toward individualized, less invasive treatment approaches, expanding availability of novel therapies and optimizing patient-specific treatment strategies will be essential. This review examines current and evolving treatment options, key challenges, and future opportunities shaping the trajectory of hemophilia management.
- 6 November 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1-8
The Understanding of the Importance of Oxidant/antioxidant Status in Hemophilia Patients with Arthropathy
- 6 November 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1-8
The Understanding of the Importance of Oxidant/antioxidant Status in Hemophilia Patients with Arthropathy
- Top Cited PapersOpen Access
- 2 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (14) , 1654-1663
Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial
Marstacimab targets the tissue factor pathway inhibitor to rebalance hemostasis. Previous phase 1 and 2 trials established marstacimab safety and efficacy in adults with severe hemophilia A (HA) or B (HB). BASIS is an open-label, marstacimab phase 3 trial in males aged 12 to 74 years with severe HA (factor VIII <1%) or moderately severe to severe HB (factor IX ≤2%). Participants without inhibitors received on-demand (OD) or routine prophylaxis (RP) therapy during a 6-month observational phase (OP) before receiving once-weekly subcutaneous 150 mg marstacimab during a 12-month active treatment phase (ATP). Primary end points were annualized bleeding rate (ABR) for treated bleeds vs previous OD or RP during the OP, and safety. Of 128 participants enrolled in the OP, 116 received marstacimab in the ATP. In the OD group (n = 33), mean ABR decreased from 39.86 (95% confidence interval [CI], 33.05-48.07) in the OP to 3.20 (95% CI, 2.10-4.88) in the ATP, demonstrating superiority of marstacimab (estimated ABR ratio, 0.080 [95% CI, 0.057-0.113]; P < .0001). In the RP group (n = 83), mean ABR decreased from 7.90 (95% CI, 5.14-10.66) in the OP to 5.09 (95% CI, 3.40-6.78) in the ATP, demonstrating noninferiority and superiority of marstacimab (estimated ABR difference, –2.81 [95% CI, –5.42 to –0.20]; P = .0349). There were no deaths or thromboembolic events. Weekly subcutaneous marstacimab reduced ABR vs OD or RP therapy in the OP in individuals with severe HA or moderately severe to severe HB without inhibitors. Marstacimab was safe and well tolerated with no unanticipated side effects. This trial was registered at www.clinicaltrials.gov as #NCT03938792.
- 2 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (14) , 1654-1663
Top Cited PapersOpen AccessMarstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial
Marstacimab targets the tissue factor pathway inhibitor to rebalance hemostasis. Previous phase 1 and 2 trials established marstacimab safety and efficacy in adults with severe hemophilia A (HA) or B (HB). BASIS is an open-label, marstacimab phase 3 trial in males aged 12 to 74 years with severe HA (factor VIII <1%) or moderately severe to severe HB (factor IX ≤2%). Participants without inhibitors received on-demand (OD) or routine prophylaxis (RP) therapy during a 6-month observational phase (OP) before receiving once-weekly subcutaneous 150 mg marstacimab during a 12-month active treatment phase (ATP). Primary end points were annualized bleeding rate (ABR) for treated bleeds vs previous OD or RP during the OP, and safety. Of 128 participants enrolled in the OP, 116 received marstacimab in the ATP. In the OD group (n = 33), mean ABR decreased from 39.86 (95% confidence interval [CI], 33.05-48.07) in the OP to 3.20 (95% CI, 2.10-4.88) in the ATP, demonstrating superiority of marstacimab (estimated ABR ratio, 0.080 [95% CI, 0.057-0.113]; P < .0001). In the RP group (n = 83), mean ABR decreased from 7.90 (95% CI, 5.14-10.66) in the OP to 5.09 (95% CI, 3.40-6.78) in the ATP, demonstrating noninferiority and superiority of marstacimab (estimated ABR difference, –2.81 [95% CI, –5.42 to –0.20]; P = .0349). There were no deaths or thromboembolic events. Weekly subcutaneous marstacimab reduced ABR vs OD or RP therapy in the OP in individuals with severe HA or moderately severe to severe HB without inhibitors. Marstacimab was safe and well tolerated with no unanticipated side effects. This trial was registered at www.clinicaltrials.gov as #NCT03938792.
- Open Access
- 1 July 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (4) , 379-383
Advances in Pediatric Lymphoblastic Lymphoma: Demographic, Clinical Characteristics, Treatment and Long-Term Outcome: A Single-Center Retrospective Analysis
Objective: Non-Hodgkin lymphoma (NHL) encompasses a broad range of lymphoid malignancies, among which lymphoblastic lymphoma (LBL) is one of the most prevalent subtypes in pediatric populations. Lymphoblastic lymphoma is further categorized into T-lymphoblastic lymphoma (T-LBL) and precursor B-lymphoblastic lymphoma (B-LBL), collectively representing approximately 20%-25% of all pediatric NHL cases. Advances in treatment strategies adapted from acute lymphoblastic leukemia (ALL) have significantly improved the prognosis of patients diagnosed with LBL. This study aims to review the institutional experience with children diagnosed with LBL and their demographic characteristics, clinical presentation, treatment outcomes, and survival rates over a period of more than 3 decades. Materials and Methods: A retrospective review was performed on children diagnosed with LBL between 1990 and 2022. Information was gathered regarding patient demographics, disease stage at diagnosis, treatment regimens, and clinical outcomes. Results: The cohort included 18 pediatric patients, 13 (72.2%) with T-LBL, and 5 (27.8%) with B-LBL. Most patients with T-LBL presented at advanced stages (III or IV), while patients with B-LBL often presented at earlier stages. T-lymphoblastic lymphoma commonly involved the mediastinum, while B-LBL was associated with skin, lymph node, and skeletal lesions. One patient died from sepsis in the 1990s and 1 from central nervous system relapse, while the rest of the patients survived. Treatment based on ALL regimens resulted in a 5-year event-free and overall survival rate of 88.5%. Conclusion: Modern treatment strategies, including those adapted from ALL regimens, have significantly improved survival outcomes for pediatric LBL patients. This study underscores the effectiveness of these treatments in achieving high survival rates. Cite this article as: Yildirim UM, Kebudi R, Şenol BK, Zülfikar B. Advances in pediatric lymphoblastic lymphoma: demographic, clinical characteristics, treatment and long-term outcome: A single-center retrospective analysis. Turk Arch Pediatr. 2025;60(4):379-383.
- 1 July 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (4) , 379-383
Open AccessAdvances in Pediatric Lymphoblastic Lymphoma: Demographic, Clinical Characteristics, Treatment and Long-Term Outcome: A Single-Center Retrospective Analysis
Objective: Non-Hodgkin lymphoma (NHL) encompasses a broad range of lymphoid malignancies, among which lymphoblastic lymphoma (LBL) is one of the most prevalent subtypes in pediatric populations. Lymphoblastic lymphoma is further categorized into T-lymphoblastic lymphoma (T-LBL) and precursor B-lymphoblastic lymphoma (B-LBL), collectively representing approximately 20%-25% of all pediatric NHL cases. Advances in treatment strategies adapted from acute lymphoblastic leukemia (ALL) have significantly improved the prognosis of patients diagnosed with LBL. This study aims to review the institutional experience with children diagnosed with LBL and their demographic characteristics, clinical presentation, treatment outcomes, and survival rates over a period of more than 3 decades. Materials and Methods: A retrospective review was performed on children diagnosed with LBL between 1990 and 2022. Information was gathered regarding patient demographics, disease stage at diagnosis, treatment regimens, and clinical outcomes. Results: The cohort included 18 pediatric patients, 13 (72.2%) with T-LBL, and 5 (27.8%) with B-LBL. Most patients with T-LBL presented at advanced stages (III or IV), while patients with B-LBL often presented at earlier stages. T-lymphoblastic lymphoma commonly involved the mediastinum, while B-LBL was associated with skin, lymph node, and skeletal lesions. One patient died from sepsis in the 1990s and 1 from central nervous system relapse, while the rest of the patients survived. Treatment based on ALL regimens resulted in a 5-year event-free and overall survival rate of 88.5%. Conclusion: Modern treatment strategies, including those adapted from ALL regimens, have significantly improved survival outcomes for pediatric LBL patients. This study underscores the effectiveness of these treatments in achieving high survival rates. Cite this article as: Yildirim UM, Kebudi R, Şenol BK, Zülfikar B. Advances in pediatric lymphoblastic lymphoma: demographic, clinical characteristics, treatment and long-term outcome: A single-center retrospective analysis. Turk Arch Pediatr. 2025;60(4):379-383.
- Top Cited PapersOpen Access
- 19 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (25) , 2966-2977
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia. This phase 3 open-label extension study (ATLAS-OLE) evaluated safety and efficacy of an AT-based dose regimen (AT-DR) in males aged ≥12 years with severe hemophilia A/B, with/without inhibitors. The original dose regimen (ODR) of 80 mg monthly was optimized to AT-DR targeting AT activity levels 15% to 35% to mitigate thrombotic risk (starting dose of 50 mg once every 2 months, individually adjusted to 20 mg once every 2 months, or 20/50/80 mg monthly as needed). Primary and secondary end points were safety and efficacy, respectively. Integrated safety analyses assessed safety of AT-DR and ODR across all fitusiran studies and integrated efficacy analyses compared efficacy of AT-DR in ATLAS-OLE with phase 3 parent study control groups. At interim data cutoff, 213 participants were enrolled on AT-DR (78% on regimens of once every 2 months). Integrated safety analyses of participants receiving AT-DR (n = 286) demonstrated that AT-DR was well tolerated. In ATLAS-OLE, median observed annualized bleeding rate (ABR) with AT-DR was 3.7 (interquartile range, 0.0-7.5). Integrated efficacy analyses demonstrated superiority of AT-DR over on-demand clotting factor concentrates (CFCs; 71% mean ABR reduction; P < .0001), and on-demand bypassing agents (BPAs; 73% mean ABR reduction; P = .0006); improvement over BPA prophylaxis (70% mean ABR reduction); and ABR comparable with that observed with CFC prophylaxis. Fitusiran AT-DR was well tolerated and maintained bleed protection with as few as 6 injections per year. This trial was registered at www.ClinicalTrials.gov as #NCT03754790.
- 19 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (25) , 2966-2977
Top Cited PapersOpen AccessSafety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia. This phase 3 open-label extension study (ATLAS-OLE) evaluated safety and efficacy of an AT-based dose regimen (AT-DR) in males aged ≥12 years with severe hemophilia A/B, with/without inhibitors. The original dose regimen (ODR) of 80 mg monthly was optimized to AT-DR targeting AT activity levels 15% to 35% to mitigate thrombotic risk (starting dose of 50 mg once every 2 months, individually adjusted to 20 mg once every 2 months, or 20/50/80 mg monthly as needed). Primary and secondary end points were safety and efficacy, respectively. Integrated safety analyses assessed safety of AT-DR and ODR across all fitusiran studies and integrated efficacy analyses compared efficacy of AT-DR in ATLAS-OLE with phase 3 parent study control groups. At interim data cutoff, 213 participants were enrolled on AT-DR (78% on regimens of once every 2 months). Integrated safety analyses of participants receiving AT-DR (n = 286) demonstrated that AT-DR was well tolerated. In ATLAS-OLE, median observed annualized bleeding rate (ABR) with AT-DR was 3.7 (interquartile range, 0.0-7.5). Integrated efficacy analyses demonstrated superiority of AT-DR over on-demand clotting factor concentrates (CFCs; 71% mean ABR reduction; P < .0001), and on-demand bypassing agents (BPAs; 73% mean ABR reduction; P = .0006); improvement over BPA prophylaxis (70% mean ABR reduction); and ABR comparable with that observed with CFC prophylaxis. Fitusiran AT-DR was well tolerated and maintained bleed protection with as few as 6 injections per year. This trial was registered at www.ClinicalTrials.gov as #NCT03754790.
- Open Access
- 28 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (8) , e31827
Keeping Hope for Dying Children and Their Families: The Experiences of Physicians and Nurses in Pediatric Oncology
Background: Hope plays a vital role in helping families navigate the challenges of pediatric cancer, fostering emotional resilience and treatment adherence, while cultural factors and healthcare professionals’ strategies help keep it alive. This study explores the lived experiences of physicians and nurses in keeping hope for dying children and their families within pediatric oncology settings.Methods: A qualitative research design was employed, with semi‐structured interviews. Participants were selected through purposive sampling. The study was conducted with 23 healthcare professionals (12 physicians and 11 nurses) working in pediatric hematology‐oncology units, ensuring at least 2 years of professional experience in Turkey. Reflexive thematic analysis was used to identify key themes.Results: Three main themes were identified: (i) The Importance of Hope—coping mechanism and continuing treatment; (ii) Challenges in Keeping Hope—balancing hope and realism, emotional responses and exhaustion, impact of relapse, and professional responsibility; (iii) Strategies for Keeping Hope—individualized communication, providing positive examples, hiding real feelings and thoughts. The findings highlight healthcare professionals' cultural and emotional complexities and underscore the delicate balance between fostering hope and addressing clinical realities.Conclusion: Keeping hope is a pivotal aspect of pediatric oncology care, enhancing emotional resilience and treatment adherence. Healthcare professionals must navigate significant challenges while employing culturally sensitive strategies to keep hope for patients and families. These findings underscore the need for training and support systems to promote effective communication, emotional resilience, and quality care in pediatric oncology settings.
- 28 May 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (8) , e31827
Open AccessKeeping Hope for Dying Children and Their Families: The Experiences of Physicians and Nurses in Pediatric Oncology
Background: Hope plays a vital role in helping families navigate the challenges of pediatric cancer, fostering emotional resilience and treatment adherence, while cultural factors and healthcare professionals’ strategies help keep it alive. This study explores the lived experiences of physicians and nurses in keeping hope for dying children and their families within pediatric oncology settings.Methods: A qualitative research design was employed, with semi‐structured interviews. Participants were selected through purposive sampling. The study was conducted with 23 healthcare professionals (12 physicians and 11 nurses) working in pediatric hematology‐oncology units, ensuring at least 2 years of professional experience in Turkey. Reflexive thematic analysis was used to identify key themes.Results: Three main themes were identified: (i) The Importance of Hope—coping mechanism and continuing treatment; (ii) Challenges in Keeping Hope—balancing hope and realism, emotional responses and exhaustion, impact of relapse, and professional responsibility; (iii) Strategies for Keeping Hope—individualized communication, providing positive examples, hiding real feelings and thoughts. The findings highlight healthcare professionals' cultural and emotional complexities and underscore the delicate balance between fostering hope and addressing clinical realities.Conclusion: Keeping hope is a pivotal aspect of pediatric oncology care, enhancing emotional resilience and treatment adherence. Healthcare professionals must navigate significant challenges while employing culturally sensitive strategies to keep hope for patients and families. These findings underscore the need for training and support systems to promote effective communication, emotional resilience, and quality care in pediatric oncology settings.
- Open Access
- 5 May 2025
- Published by Wiley in Haemophilia
- Vol. 31 (5) , 903-911
Real‐World Unmet Needs of Patients With Haemophilia A and Haemophilia B With or Without Inhibitors: End‐of‐Study Results From the explorer6 Non‐Interventional Study
Introduction: Haemophilia is associated with high disease and treatment burdens. Prospective evaluation of data from patients with haemophilia helps understand and define unmet needs, optimise treatment and improve healthcare outcomes. Aim: To present end‐of‐study data from explorer6 (NCT03741881), a prospective, non‐interventional study across multiple countries in patients with haemophilia (haemophilia A or B without [HA or HB] or with inhibitors [HAwI or HBwI]). Methods: Patients ≥12 years old with severe HA, severe/moderate HB or HAwI/HBwI of any severity were treated according to the local standard of care (SoC). The number of bleeding episodes from enrolment up to a maximum of 115 weeks, physical activity based on data collected by a wrist‐worn physical activity tracker, target joints and Haemophilia Joint Health Score (HJHS) measurements were assessed. Results: A total of 231 patients across 33 countries were enrolled. The mean annualised bleeding rate (ABR) (standard deviation) for treated bleeding episodes was investigated for patients receiving prophylaxis (HA: 4.7 [5.9]; HB: 2.2 [3.0]; HAwI: 10.3 [8.5]; HBwI: 12.4 [14.1]) and those receiving on‐demand (OnD) treatment (HA: 21.5 [17.7]; HB: 10.5 [8.6]; HAwI: 15.2 [14.8]; HBwI: 9.3 [13.3]). Physical activity levels were lowest among patients with HBwI. Target joints were similar among haemophilia types and treatments. Overall, mean and median HJHS total scores were lower for patients receiving prophylaxis compared with OnD treatment. Conclusion: The explorer6 study assessed a large haemophilia patient population in a real‐world setting across 33 countries. The results indicate that an unmet need remains among patients receiving OnD treatment and those with inhibitors. Trial Registration : ClinicalTrials.gov identifier: NCT03741881
- 5 May 2025
- Published by Wiley in Haemophilia
- Vol. 31 (5) , 903-911
Open AccessReal‐World Unmet Needs of Patients With Haemophilia A and Haemophilia B With or Without Inhibitors: End‐of‐Study Results From the explorer6 Non‐Interventional Study
Introduction: Haemophilia is associated with high disease and treatment burdens. Prospective evaluation of data from patients with haemophilia helps understand and define unmet needs, optimise treatment and improve healthcare outcomes. Aim: To present end‐of‐study data from explorer6 (NCT03741881), a prospective, non‐interventional study across multiple countries in patients with haemophilia (haemophilia A or B without [HA or HB] or with inhibitors [HAwI or HBwI]). Methods: Patients ≥12 years old with severe HA, severe/moderate HB or HAwI/HBwI of any severity were treated according to the local standard of care (SoC). The number of bleeding episodes from enrolment up to a maximum of 115 weeks, physical activity based on data collected by a wrist‐worn physical activity tracker, target joints and Haemophilia Joint Health Score (HJHS) measurements were assessed. Results: A total of 231 patients across 33 countries were enrolled. The mean annualised bleeding rate (ABR) (standard deviation) for treated bleeding episodes was investigated for patients receiving prophylaxis (HA: 4.7 [5.9]; HB: 2.2 [3.0]; HAwI: 10.3 [8.5]; HBwI: 12.4 [14.1]) and those receiving on‐demand (OnD) treatment (HA: 21.5 [17.7]; HB: 10.5 [8.6]; HAwI: 15.2 [14.8]; HBwI: 9.3 [13.3]). Physical activity levels were lowest among patients with HBwI. Target joints were similar among haemophilia types and treatments. Overall, mean and median HJHS total scores were lower for patients receiving prophylaxis compared with OnD treatment. Conclusion: The explorer6 study assessed a large haemophilia patient population in a real‐world setting across 33 countries. The results indicate that an unmet need remains among patients receiving OnD treatment and those with inhibitors. Trial Registration : ClinicalTrials.gov identifier: NCT03741881
- Open Access
- 24 April 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e66770
Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises in Improving Balance and Gait in People With Hemophilia: Protocol for a Randomized Controlled Trial
Background: Inherited bleeding disorders involve prolonged bleeding due to clotting protein deficiencies, with hemophilia A and B being the most common types. The severity of bleeding in people with hemophilia depends on the deficient factor level. Treatment includes coagulation factor concentrates, nonreplacement preparations, gene therapies, and physiotherapy, whereby bleeding is prevented, symptoms are reduced, and the quality of life is improved. Closed kinetic chain exercises improve joint stability and neuromuscular control by stabilizing the proximal base, making them favored in musculoskeletal rehabilitation. Proprioceptive exercise training improves the sensorimotor system’s adaptability and injury prevention through tailored programs involving progressively complex movements and surfaces. Objective: The aim of this study is to investigate the effects of closed kinetic chain exercises and proprioceptive exercise training on improving balance and walking in people with hemophilia. Methods: This study is a 3-arm, parallel-group randomized controlled trial with 63 people with hemophilia aged 13-25 years who meet the inclusion criteria. The primary outcome measures are medio-lateral swing, anterior-posterior swing, walking speed, and Hemophilia Joint Health Score. Secondary outcome measures are kinematic assessment of gait, one-leg stand test, 6-minute walk distance (6MWD) test, proprioception assessment, and the Functional Independence Score in Hemophilia. Participants will be evaluated with the Biodex balance system for postural sway, 10-meters walking test for gait speed, Hemophilia Joint Health Score for joint health, Kinovea 2D motion analysis for kinematic evaluation of gait, one-leg stand test for balance measurement, 6MWD for functional capacity, digital goniometer for proprioception, and Functional Independence Score in Hemophilia for functional independence. Participants will be randomly assigned to a closed kinetic chain exercise group, a proprioceptive exercise group, or a control group. All participants in exercise training groups will receive a 30-minute education session on joint protection techniques and energy conservation prior to the first exercise session. Closed kinetic chain exercises will include progressive lower limb exercises of approximately 45 minutes each session. Proprioceptive exercise training will focus on vibration training; reposition exercises and proprioception exercises will be administered to increase proprioceptive input for the same duration as the other group. The control group will receive no intervention. All participants will undergo 24 exercise sessions (2 days a week for 12 weeks). After the treatment, the initial measurements will be repeated. Results: This study began in September 2023 and is scheduled to be completed in May 2025. A total of 34 participants have completed the study to date. Conclusions: This study will investigate the effects of 2 different exercises on functional parameters in people with hemophilia. The effects of different exercise protocols on parameters such as postural sway, walking speed, and joint health will be evaluated. It is predicted that both exercise methods may have positive effects on balance and gait. Trial Registration: Clinical Trials.gov NCT05879549; https://clinicaltrials.gov/study/NCT05879549 International Registered Report Identifier (IRRID): DERR1-10.2196/66770
- 24 April 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e66770
Open AccessComparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises in Improving Balance and Gait in People With Hemophilia: Protocol for a Randomized Controlled Trial
Background: Inherited bleeding disorders involve prolonged bleeding due to clotting protein deficiencies, with hemophilia A and B being the most common types. The severity of bleeding in people with hemophilia depends on the deficient factor level. Treatment includes coagulation factor concentrates, nonreplacement preparations, gene therapies, and physiotherapy, whereby bleeding is prevented, symptoms are reduced, and the quality of life is improved. Closed kinetic chain exercises improve joint stability and neuromuscular control by stabilizing the proximal base, making them favored in musculoskeletal rehabilitation. Proprioceptive exercise training improves the sensorimotor system’s adaptability and injury prevention through tailored programs involving progressively complex movements and surfaces. Objective: The aim of this study is to investigate the effects of closed kinetic chain exercises and proprioceptive exercise training on improving balance and walking in people with hemophilia. Methods: This study is a 3-arm, parallel-group randomized controlled trial with 63 people with hemophilia aged 13-25 years who meet the inclusion criteria. The primary outcome measures are medio-lateral swing, anterior-posterior swing, walking speed, and Hemophilia Joint Health Score. Secondary outcome measures are kinematic assessment of gait, one-leg stand test, 6-minute walk distance (6MWD) test, proprioception assessment, and the Functional Independence Score in Hemophilia. Participants will be evaluated with the Biodex balance system for postural sway, 10-meters walking test for gait speed, Hemophilia Joint Health Score for joint health, Kinovea 2D motion analysis for kinematic evaluation of gait, one-leg stand test for balance measurement, 6MWD for functional capacity, digital goniometer for proprioception, and Functional Independence Score in Hemophilia for functional independence. Participants will be randomly assigned to a closed kinetic chain exercise group, a proprioceptive exercise group, or a control group. All participants in exercise training groups will receive a 30-minute education session on joint protection techniques and energy conservation prior to the first exercise session. Closed kinetic chain exercises will include progressive lower limb exercises of approximately 45 minutes each session. Proprioceptive exercise training will focus on vibration training; reposition exercises and proprioception exercises will be administered to increase proprioceptive input for the same duration as the other group. The control group will receive no intervention. All participants will undergo 24 exercise sessions (2 days a week for 12 weeks). After the treatment, the initial measurements will be repeated. Results: This study began in September 2023 and is scheduled to be completed in May 2025. A total of 34 participants have completed the study to date. Conclusions: This study will investigate the effects of 2 different exercises on functional parameters in people with hemophilia. The effects of different exercise protocols on parameters such as postural sway, walking speed, and joint health will be evaluated. It is predicted that both exercise methods may have positive effects on balance and gait. Trial Registration: Clinical Trials.gov NCT05879549; https://clinicaltrials.gov/study/NCT05879549 International Registered Report Identifier (IRRID): DERR1-10.2196/66770
- Open Access
- 27 February 2025
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (1) , 51-60
Inflammatory myofibroblastic tumors in children: clinical characteristics and treatment outcomes with a focus on targeted therapies
Background. Inflammatory myofibroblastic tumors (IMTs) are rare neoplasms in children. Traditionally, surgical resection has been the primary treatment modality with limited efficacy reported for conventional chemotherapy and radiation therapy. Recently, targeted therapies have emerged as potential options for selected cases. This study aimed to evaluate the demographic, clinical, laboratory, and radiological characteristics, as well as treatment outcomes, in children diagnosed with IMTs. Methods. This study involved a retrospective review of medical records for eight children diagnosed with IMTs between 1990 and 2022. We collected demographic, clinical, laboratory, and radiological data, as well as treatment outcomes. Data on tumor characteristics, surgical procedures, and chemotherapy or targeted therapy treatments were extracted. Results. The mean age at diagnosis was 9 years. None presented with metastatic disease at the time of diagnosis. Anaplastic lymphoma kinase (ALK) positivity was identified in tumor tissue from five patients. Among the six patients who underwent surgical resection, three achieved negative surgical margins. Of the three patients with positive surgical margins, one underwent re-resection, local and metastatic recurrences were noted in another, and one was started on crizotinib. A patient with an inoperable tumor at diagnosis was initiated on crizotinib and achieved complete remission. Ceritinib was administered to a patient with YWHAE-ROS fusion, resulting in more than 90% reduction in tumor volume. The median follow-up time was 67.5 months. The five-year overall survival and event-free survival rates for the cohort were 85.7% and 72.9%, respectively. Conclusions. While surgical resection remains the cornerstone of treatment for IMTs, favorable outcomes can be achieved with chemotherapy and targeted therapies in selected cases. Increasing the utilization of targeted therapies may be beneficial, particularly through molecular studies aimed at minimizing the side effects associated with conventional chemotherapy.
- 27 February 2025
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (1) , 51-60
Open AccessInflammatory myofibroblastic tumors in children: clinical characteristics and treatment outcomes with a focus on targeted therapies
Background. Inflammatory myofibroblastic tumors (IMTs) are rare neoplasms in children. Traditionally, surgical resection has been the primary treatment modality with limited efficacy reported for conventional chemotherapy and radiation therapy. Recently, targeted therapies have emerged as potential options for selected cases. This study aimed to evaluate the demographic, clinical, laboratory, and radiological characteristics, as well as treatment outcomes, in children diagnosed with IMTs. Methods. This study involved a retrospective review of medical records for eight children diagnosed with IMTs between 1990 and 2022. We collected demographic, clinical, laboratory, and radiological data, as well as treatment outcomes. Data on tumor characteristics, surgical procedures, and chemotherapy or targeted therapy treatments were extracted. Results. The mean age at diagnosis was 9 years. None presented with metastatic disease at the time of diagnosis. Anaplastic lymphoma kinase (ALK) positivity was identified in tumor tissue from five patients. Among the six patients who underwent surgical resection, three achieved negative surgical margins. Of the three patients with positive surgical margins, one underwent re-resection, local and metastatic recurrences were noted in another, and one was started on crizotinib. A patient with an inoperable tumor at diagnosis was initiated on crizotinib and achieved complete remission. Ceritinib was administered to a patient with YWHAE-ROS fusion, resulting in more than 90% reduction in tumor volume. The median follow-up time was 67.5 months. The five-year overall survival and event-free survival rates for the cohort were 85.7% and 72.9%, respectively. Conclusions. While surgical resection remains the cornerstone of treatment for IMTs, favorable outcomes can be achieved with chemotherapy and targeted therapies in selected cases. Increasing the utilization of targeted therapies may be beneficial, particularly through molecular studies aimed at minimizing the side effects associated with conventional chemotherapy.